Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Medical Research Journal
MENU
Shortcuts Submit an article Author Guidelines Reviewers 2023 Focus and Scope

open access

Vol 7, No 4 (2022)
Review article
Published online: 2022-11-22
View PDF Download PDF file
Get Citation

Granulocyte transfusion vs. neutropenia — is there a chance to win this battle?

Artur Szumowski12, Piotr Marek Radziwon12
DOI: 10.5603/MRJ.a2022.0048
·
Medical Research Journal 2022;7(4):321-332.
Affiliations
  1. Regional Centre for Transfusion Medicine, Bialystok, Poland
  2. Department of Haematology, Medical University of Bialystok, Bialystok, Poland

open access

Vol 7, No 4 (2022)
REVIEW ARTICLES
Published online: 2022-11-22

Abstract

Bacterial and fungal infections remain a significant cause of morbidity and mortality in patients with prolonged severe neutropenia that results from the treatment of an underlying haematological malignancy. Granulocyte transfusions have been broadly used to prevent and/or treat life-threatening infections in these patients. The purpose of this review was to answer the question, “Are granulocyte transfusions effective in combating hazardous infections in haematology/oncology patients with neutropenia?”.

Abstract

Bacterial and fungal infections remain a significant cause of morbidity and mortality in patients with prolonged severe neutropenia that results from the treatment of an underlying haematological malignancy. Granulocyte transfusions have been broadly used to prevent and/or treat life-threatening infections in these patients. The purpose of this review was to answer the question, “Are granulocyte transfusions effective in combating hazardous infections in haematology/oncology patients with neutropenia?”.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

haematological malignancy, neutropenia, bacterial infection, fungal infection, leukapheresis, granulocyte transfusion

About this article
Title

Granulocyte transfusion vs. neutropenia — is there a chance to win this battle?

Journal

Medical Research Journal

Issue

Vol 7, No 4 (2022)

Article type

Review article

Pages

321-332

Published online

2022-11-22

Page views

3398

Article views/downloads

348

DOI

10.5603/MRJ.a2022.0048

Bibliographic record

Medical Research Journal 2022;7(4):321-332.

Keywords

haematological malignancy
neutropenia
bacterial infection
fungal infection
leukapheresis
granulocyte transfusion

Authors

Artur Szumowski
Piotr Marek Radziwon

References (84)
  1. Ang AL, Linn YC. Treatment of severe neutropenic sepsis with granulocyte transfusion in the current era - experience from an adult haematology unit in Singapore. Transfus Med. 2011; 21(1): 13–24.
    CrossRefPubMed
  2. Harris DJ. The resurgence of granulocyte transfusions. J Infus Nurs. 2009; 32(6): 323–329.
    CrossRefPubMed
  3. Brecher G, Wilbur KM, Cronkite EP. Transfusion of separated leukocytes into irradiated dogs with aplastic marrows. Proc Soc Exp Biol Med. 1953; 84(1): 54–56.
    CrossRefPubMed
  4. Dale DC, Reynolds HY, Pennington JE, et al. Experimental Pseudomonas pneumonia in leukopenic dogs: comparison of therapy with antibiotics and granulocyte transfusions. Blood. 1976; 47(5): 869–876.
    PubMed
  5. Ruthe RC, Andersen BR, Cunningham BL, et al. Efficacy of granulocyte transfusions in the control of systemic candidiasis in the leukopenic host. Blood. 1978; 52(3): 493–498.
    PubMed
  6. Freirich EJ, Levin RH, Whang J, et al. The function and fate of transfused leukocytes from donors with chronic myelocytic leukemia in leukopenic recipients. Ann N Y Acad Sci. 1964; 113: 1081–1089.
    CrossRefPubMed
  7. Stanworth SJ, Massey E, Hyde C, et al. Granulocyte transfusions for treating infections in patients with neutropenia or neutrophil dysfunction. Cochrane Database Syst Rev. 2005(3): CD005339.
    CrossRefPubMed
  8. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplant. 2002; 29(1): 15–19.
    CrossRefPubMed
  9. Bearden 3rd JD, Coltman CA, Ratkin GA. Hydroxyethyl starch and prednisone as adjuncts to granulocyte collection. Transfusion. 1977; 17(2): 141–146.
    CrossRefPubMed
  10. Iacone A, Di Bartolomeo P, Di Girolamo G, et al. Hydroxyethyl starch and steroid improved collection of normal granulocytes with continuous flow centrifugation gravity leukapheresis. Haematologica. 1981; 66(5): 645–655.
    PubMed
  11. Mishler JM, Hester JP, Huestis DW, et al. Dosage and scheduling regimens for erythrocyte-sedimenting macromolecules. J Clin Apher. 1983; 1(3): 130–143.
    CrossRefPubMed
  12. Glasser L, Huestis DW. Characteristics of stored granulocytes collected from donors stimulated with dexamethasone. Transfusion. 1979; 19(1): 53–56.
    CrossRefPubMed
  13. Chanock S, Gorlin J. Granulocyte transfusions. Time for a second look. Infect Dis Clin North Am. 1996; 10(2): 327–343.
    CrossRefPubMed
  14. Stroncek DF, Leitman SF. Granulocyte transfusions: a review. Immunohematology. 1998; 14(3): 101–108.
    PubMed
  15. Marfin AA, Price TH. Granulocyte transfusion therapy. J Intensive Care Med. 2015; 30(2): 79–88.
    CrossRefPubMed
  16. Mary JY. Normal human granulopoiesis revisited. II. Bone marrow data. Biomed Pharmacother. 1985; 39(2): 66–77.
    PubMed
  17. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 2014; 14(5): 302–314.
    CrossRefPubMed
  18. Borregaard N. Neutrophils, from marrow to microbes. Immunity. 2010; 33(5): 657–670.
    CrossRefPubMed
  19. Curi R, Levada-Pires AC, Silva EB, et al. The critical role of cell metabolism for essential neutrophil functions. Cell Physiol Biochem. 2020; 54(4): 629–647.
    CrossRefPubMed
  20. Summers C, Rankin SM, Condliffe AM, et al. Neutrophil kinetics in health and disease. Trends Immunol. 2010; 31(8): 318–324.
    CrossRefPubMed
  21. Chan YK, Tsai MH, Huang DC, et al. Leukocyte nucleus segmentation and nucleus lobe counting. BMC Bioinformatics. 2010; 11: 558.
    CrossRefPubMed
  22. Cowland JB, Borregaard N. Granulopoiesis and granules of human neutrophils. Immunol Rev. 2016; 273(1): 11–28.
    CrossRefPubMed
  23. Faurschou M, Borregaard N. Neutrophil granules and secretory vesicles in inflammation. Microbes Infect. 2003; 5(14): 1317–1327.
    CrossRefPubMed
  24. Nüsse O, Lindau M. The dynamics of exocytosis in human neutrophils. J Cell Biol. 1988; 107(6 Pt 1): 2117–2123.
    CrossRefPubMed
  25. Borregaard N, Sørensen OE, Theilgaard-Mönch K. Neutrophil granules: a library of innate immunity proteins. Trends Immunol. 2007; 28(8): 340–345.
    CrossRefPubMed
  26. Kumar R, Azam S, Sullivan JM, et al. Brain ischemia and reperfusion activates the eukaryotic initiation factor 2alpha kinase, PERK. J Neurochem. 2001; 77(5): 1418–1421.
    CrossRefPubMed
  27. Selvatici R, Falzarano S, Mollica A, et al. Signal transduction pathways triggered by selective formylpeptide analogues in human neutrophils. Eur J Pharmacol. 2006; 534(1-3): 1–11.
    CrossRefPubMed
  28. Witko-Sarsat V, Rieu P, Descamps-Latscha B, et al. Neutrophils: molecules, functions and pathophysiological aspects. Lab Invest. 2000; 80(5): 617–653.
    CrossRefPubMed
  29. Hatanaka E, Shimomi FM, Curi R, et al. Sodium chloride inhibits cytokine production by lipopolysaccharide-stimulated human neutrophils and mononuclear cells. Shock. 2007; 27(1): 32–35.
    CrossRefPubMed
  30. Levada-Pires AC, Lambertucci RH, Mohamad M, et al. Exercise training raises expression of the cytosolic components of NADPH oxidase in rat neutrophils. Eur J Appl Physiol. 2007; 100(2): 153–160.
    CrossRefPubMed
  31. de Oliveira S, Rosowski EE, Huttenlocher A. Neutrophil migration in infection and wound repair: going forward in reverse. Nat Rev Immunol. 2016; 16(6): 378–391.
    CrossRefPubMed
  32. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. Science. 2004; 303(5663): 1532–1535.
    CrossRefPubMed
  33. Mastronardi R, Cleophax S, Begué S, et al. [Preparation of pooled granulocytes concentrates from whole blood buffy coats (PGC) as an alternative to apheresis]. Transfus Clin Biol. 2019; 26(3): 164–170.
    CrossRefPubMed
  34. Bensinger WI, Price TH, Dale DC, et al. The effects of daily recombinant human granulocyte colony-stimulating factor administration on normal granulocyte donors undergoing leukapheresis. Blood. 1993; 81(7): 1883–1888.
    PubMed
  35. Caspar CB, Seger RA, Burger J, et al. Effective stimulation of donors for granulocyte transfusions with recombinant methionyl granulocyte colony-stimulating factor. Blood. 1993; 81(11): 2866–2871.
    PubMed
  36. Leavey PJ, Thurman G, Ambruso DR. Functional characteristics of neutrophils collected and stored after administration of G-CSF. Transfusion. 2000; 40(4): 414–419.
    CrossRefPubMed
  37. Bux J, Cassens U, Dielschneider T, et al. Tolerance of granulocyte donors towards granulocyte colony-stimulating factor stimulation and of patients towards granulocyte transfusions: results of a multicentre study. Vox Sang. 2003; 85(4): 322–325.
    CrossRefPubMed
  38. de la Rubia J, de Arriba F, Arbona C, et al. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. Haematologica. 2008; 93(5): 735–740.
    CrossRefPubMed
  39. Hölig K. G-CSF in healthy allogeneic stem cell donors. Transfus Med Hemother. 2013; 40(4): 225–235.
    CrossRefPubMed
  40. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood. 2012; 119(7): 1757–1767.
    CrossRefPubMed
  41. Gutierrez-Delgado F, Bensinger W. Safety of granulocyte colony-stimulating factor in normal donors. Curr Opin Hematol. 2001; 8(3): 155–160.
    CrossRefPubMed
  42. Wiedermann CJ, Joannidis M. Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med. 2014; 40(2): 160–170.
    CrossRefPubMed
  43. Jendiroba DB, Freireich EJ. Granulocyte transfusions: from neutrophil replacement to immunereconstitution. Blood Rev. 2000; 14(4): 219–227.
    CrossRefPubMed
  44. Hubel K, Rodger E, Gaviria JM, et al. Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factor. Transfusion. 2005; 45(12): 1876–1889.
    CrossRefPubMed
  45. Schmitt A, Reinhardt P, Schmitt M, et al. Functional state of steroid- versus g-csf-mobilized granulocytes: considerations about the storage of granulocyte concentrates for neutropenic patients. Transfus Med Hemother. 2002; 29: 57–64.
    CrossRef
  46. Patrone F, Dallegri F, Brema F, et al. In vitro function of chronic myelocytic leukemia granulocytes. Effects of irradiation and storage. Tumori. 1979; 65(1): 27–37.
    CrossRefPubMed
  47. Netelenbos T, Massey E, de Wreede LC, et al. The burden of invasive infections in neutropenic patients: incidence, outcomes, and use of granulocyte transfusions. Transfusion. 2019; 59(1): 160–168.
    CrossRefPubMed
  48. Pammi M, Brocklehurst P. Granulocyte transfusions for neonates with confirmed or suspected sepsis and neutropenia. Cochrane Database Syst Rev. 2011; 2011(10): CD003956.
    CrossRefPubMed
  49. Seidel MG, Peters C, Wacker A, et al. Randomized phase III study of granulocyte transfusions in neutropenic patients. Bone Marrow Transplant. 2008; 42(10): 679–684.
    CrossRefPubMed
  50. Price TH. Granulocyte transfusion: current status. Semin Hematol. 2007; 44(1): 15–23.
    CrossRefPubMed
  51. Solomou EE, Salamaliki C, Lagadinou M. How to make the right diagnosis in neutropenia. Clin Hematol Int. 2021; 3(2): 41–46.
    CrossRefPubMed
  52. Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol. 2013; 50(3): 198–206.
    CrossRefPubMed
  53. Rider NL, Jameson MB, Creech CB. Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease. J Pediatric Infect Dis Soc. 2018; 7(suppl_1): S2–S5.
    CrossRefPubMed
  54. Lozano ML, Rivera J, Sánchez-Guiu I, et al. Towards the targeted management of Chediak-Higashi syndrome. Orphanet J Rare Dis. 2014; 9: 132.
    CrossRefPubMed
  55. Drewniak A, Kuijpers TW. Granulocyte transfusion therapy: randomization after all? Haematologica. 2009; 94(12): 1644–1648.
    CrossRefPubMed
  56. Higby DJ, Yates JW, Henderson ES, et al. Filtration leukapheresis for granulocyte transfusion therapy. Clinical and laboratory studies. N Engl J Med. 1975; 292(15): 761–766.
    CrossRefPubMed
  57. van de Wetering MD, Weggelaar N, Offringa M, et al. Granulocyte transfusions in neutropaenic children: a systematic review of the literature. Eur J Cancer. 2007; 43(14): 2082–2092.
    CrossRefPubMed
  58. Dutcher JP, Kendall J, Norris D, et al. Granulocyte transfusion therapy and amphotericin B: adverse reactions? Am J Hematol. 1989; 31(2): 102–108.
    CrossRefPubMed
  59. Wright DG, Robichaud KJ, Pizzo PA, et al. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions. N Engl J Med. 1981; 304(20): 1185–1189.
    CrossRefPubMed
  60. Bow EJ, Schroeder ML, Louie TJ. Pulmonary complications in patients receiving granulocyte transfusions and amphotericin B. Can Med Assoc J. 1984; 130(5): 593–597.
    PubMed
  61. Segal BH, Leto TL, Gallin JI, et al. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000; 79(3): 170–200.
    CrossRefPubMed
  62. Ajitkumar A, Yarrarapu SNS, Ramphul K. Chediak Higashi syndrome. StatPearls, Treasure Island 2022.
  63. Sharma S, Sharma P, Tyler LN. Transfusion of blood and blood products: indications and complications. Am Fam Physician. 2011; 83(6): 719–724.
    PubMed
  64. Goel R, Tobian AAR, Shaz BH. Noninfectious transfusion-associated adverse events and their mitigation strategies. Blood. 2019; 133(17): 1831–1839.
    CrossRefPubMed
  65. Fung MK, Eder AF, Spitalnik SL. Technical Manual. AABB, Bethesda 2017: 457-488, 505-526,–569-598.
  66. Bandarenko N, King K. Blood transfusion therapy: a physician’s handbook. AABB, Bethesda 2017: 1-52, 141-170, 221-256.
  67. Popovsky MA. Transfusion Reactions. AABB, Bethesda 2012: 1-288, 327-338.
  68. Delaney M, Wendel S, Bercovitz R, et al. Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Transfusion reactions: prevention, diagnosis, and treatment. Lancet. 2016; 388(10061): 2825–2836.
    CrossRefPubMed
  69. Sweeney J, Lozano M. Platelet Transfusion Therapy. AABB, Bethesda 2013: 229-320, 371-398, 493-566.
  70. Busch MP, Bloch EM, Kleinman S. Prevention of transfusion-transmitted infections. Blood. 2019; 133(17): 1854–1864.
    CrossRefPubMed
  71. Eder AF, Goldman M. How do I investigate septic transfusion reactions and blood donors with culture-positive platelet donations? Transfusion. 2011; 51(8): 1662–1668.
    CrossRefPubMed
  72. Bolton-Maggs PHB. Conference report: the 2015 SHOT symposium and report - what's new? Transfus Med. 2015; 25(5): 295–298.
    CrossRefPubMed
  73. Murphy EL, Kwaan N, Looney MR, et al. TRALI Study Group. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med. 2013; 126(4): 357.e29–357.e38.
    CrossRefPubMed
  74. Piccin A, Cronin M, Brady R, et al. Transfusion-associated circulatory overload in Ireland: a review of cases reported to the National Haemovigilance Office 2000 to 2010. Transfusion. 2015; 55(6): 1223–1230.
    CrossRefPubMed
  75. Semple JW, Rebetz J, Kapur R. Transfusion-associated circulatory overload and transfusion-related acute lung injury. Blood. 2019; 133(17): 1840–1853.
    CrossRefPubMed
  76. Popovsky MA. Transfusion-associated circulatory overload: the plot thickens. Transfusion. 2009; 49(1): 2–4.
    CrossRefPubMed
  77. Kim KiH, Lim HJ, Kim JS, et al. Therapeutic granulocyte transfusions for the treatment of febrile neutropenia in patients with hematologic diseases: a 10-year experience at a single institute. Cytotherapy. 2011; 13(4): 490–498.
    CrossRefPubMed
  78. Raad II, Chaftari AM, Al Shuaibi MM, et al. Granulocyte transfusions in hematologic malignancy patients with invasive pulmonary aspergillosis: outcomes and complications. Ann Oncol. 2013; 24(7): 1873–1879.
    CrossRefPubMed
  79. Safdar A, Rodriguez G, Zuniga J, et al. Use of healthy-donor granulocyte transfusions to treat infections in neutropenic patients with myeloid or lymphoid neoplasms: experience in 74 patients treated with 373 granulocyte transfusions. Acta Haematol. 2014; 131(1): 50–58.
    CrossRefPubMed
  80. Wang H, Wu Y, Fu R, et al. Granulocyte transfusion combined with granulocyte colony stimulating factor in severe infection patients with severe aplastic anemia: a single center experience from China. PLoS ONE. 2014; 9(2): e88148.
    CrossRefPubMed
  81. Kadri SS, Remy KE, Strich JR, et al. Role of granulocyte transfusions in invasive fusariosis: systematic review and single-center experience. Transfusion. 2015; 55(9): 2076–2085.
    CrossRefPubMed
  82. Price TH, Boeckh M, Harrison RW, et al. Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. Blood. 2015; 126(18): 2153–2161.
    CrossRefPubMed
  83. Teofili L, Valentini CG, Di Blasi R, et al. Dose-dependent effect of granulocyte transfusions in hematological patients with febrile neutropenia. PLoS One. 2016; 11(8): e0159569.
    CrossRefPubMed
  84. Garg A, Gupta A, Mishra A, et al. Role of granulocyte transfusions in combating life-threatening infections in patients with severe neutropenia: Experience from a tertiary care centre in North India. PLoS One. 2018; 13(12): e0209832.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl